Abstract
A unique feature of COVID-19 interstitial pneumonia is an abrupt progression to respiratory failure. Our calculation shows that this abrupt deteriorate may be caused by a sudden shift in the spread of virus-laden bioaerosols through the airways to many different regions of the lungs from the initial site of infection.
Electronic supplementary material
The online version of this article (10.1007/s10439-020-02676-w) contains supplementary material, which is available to authorized users.
On the CDC website1 it says “Clinicians should be aware of the potential for some patients (of COVID-19) to rapidly deteriorate one week after illness onset”. The concept of “cytokine storm”4 is discussed to explain this rapid deterioration. But why does this happen several days after the initial infection? While many mechanisms possibly contribute to spread of the infection, such as lymphatic circulation, we hypothesize that a major driver of the abrupt deterioration several days after the initial infection is caused by a sudden shift in the spread of virus-laden bioaerosols through the airways to many different regions of the lungs from the initial site of infection. Clinically, severe SARS COV-2 infections exhibit multi-region patchy patterns of ground-glass opacity (GGO) throughout the lungs detected by computed tomography (CT).3 This CT presentation is a unique characteristic of COVID-19 and is consistent with our hypothesis.
To explore this possibility, we have made a computer simulation. Suppose some part of the lung is initially infected (Figure 1a). Pulmonary edema develops locally and a meniscus with virus-laden fluid may be formed. During breathing, the meniscus is stretched and can rupture, releasing a number of small droplets called bioaerosols.2 The bioaerosols move toward the airway opening with the expired air; while most of the bioaerosols exit the body, some of them remain suspended in the airways. In the next inhalation, some of the exited particles may reenter the lungs with little deposition due to the low level of diffusion. The particles, which remain in the lung, are likely to retrace their path back to the original position (Figure 1b).
As the disease progresses, however, the distribution of airflow in the lungs changes. The infected part of the lungs contributes to a decreased volume of airflow, altering the airflow dynamics, and, at the same time, an increased production of virus-laden bioaerosols. This shift of airflow pattern distributes virus-laden bioaersols to other, even distant, parts of the lungs (Figure 1c). If multiple areas of the lungs are simultaneously infected, an overwhelming innate immune response may occur resulting in a widely-distributed “cytokine storm”. Considering the negligible (but non-zero) diffusivity of bioaerosols, the observation that the deterioration occurs several days after the initial infection. Our hypothesis suggests that targeting therapies to slow primary GGO lesion growth and to control airflow patterns could slow intra-lung viral spreading and help prevent the rapid respiratory deterioration observed in severe COVID-19 patients.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Author Contributions
AT: designed the study. NF and IS: performed the numerical simulation. NF, IS and AT: designed and produced figures and videos. NF, IS, KH, and AT: reviewed, analyzed, and interpreted the data. AT: wrote the note. All authors discussed the results and commented on the letter.
Funding
None.
Conflict of interest
All authors state no financial associations with this work.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.CDC Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
- 2.Malashenko A, Tsuda A, Haber S. Propagation and breakup of liquid menisci and aerosol generation in small airways. J. Aerosol. Med. Pulm. Drug Deliv. 2009;22(4):341–353. doi: 10.1089/jamp.2008.0696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR. 2020;215:1–7. doi: 10.2214/AJR.20.23034. [DOI] [PubMed] [Google Scholar]
- 4.Tisoncik JR, Korth MJ, Cameron P, Simmons CP, Farrar J, Martin TR, Katzea MG. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012;76(1):16–32. doi: 10.1128/MMBR.05015-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.